A new study reports that microRNA-124-3p directly targets the AHR gene to activate autophagy, suppressing stomach ...
A new review suggests that gut-derived short-chain fatty acids regulate kidney immune responses and may influence the ...
Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the ...
US FDA accepts for review uniQure’s BLA for ifezuntirgene inilparvovec for the treatment of Huntington’s disease: Lexington, Massachusetts Tuesday, November 3, 2026, 16:00 Hrs ...
uniQure N.V. ( QURE ), a gene therapy company, on Monday announced the acceptance of the biologics license application ( BLA) for Ifezuntirgene inilparvovec in treating Huntington's disease by the U.S ...
The FDA has accepted uniQure's Biologics License Application for ifezuntirgene inilparvovec, a one-time gene therapy for Huntington's ...
The FDA has set a May 1 target action date for uniQure’s Huntington’s disease gene therapy candidate ifezuntirgene inilparvovec, after accepting the company’s Biologics License Application (BLA) under ...
Toothbrushes have undergone no substantive improvements beyond their mechanical function for about 1118 years to date.
A discussion of ethical issues and best practices for attorneys using AI tools while providing legal services, including ...
Most Admired CEOs honors talented business CEOs and nonprofit executive directors throughout Maryland whose leadership and vision is admired by those around them.
Qure (QURE) stock drops 2.98% to $24.09 despite FDA Priority Review for its Huntington’s disease gene therapy, with a May 2027 decision date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results